46. Malignant rheumatoid arthritis Clinical trials / Disease details
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
Showing 1 to 10 of 11 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs051220027 | 25/05/2022 | 25/05/2022 | Examination of the efficacy of Peficitinib reduction in RA patients in sustained remission | Japan post-marketing study of Peficitinib use in RA patients (JASPER-reduction Study) | Rheumatoid arthritis;M0690 | RA patients who devided into into Peficitinib 150 mg and 100 mg groups, and their efficacy and safety will be examined among each group. RA patients who devided into into Peficitinib150 mg and 100 mg groups, and their efficacy and safety ... | Hashimoto Motomu | NULL | Recruiting | >= 20age old | Not applicable | Both | 60 | N/A | Japan |
| 2 | NCT03971253 (ClinicalTrials.gov) | September 2, 2019 | 30/5/2019 | Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis Japan Post-Marketing Surveillance for Peficitinibto Assess Safety and Effectiveness in the Patients ... | Japan Post-Marketing Surveillance - Specified Drug Use-results Survey for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis Japan Post-Marketing Surveillance - Specified Drug Use-results Survey for Peficitinibto Assess Safet ... | Rheumatoid Arthritis (RA) | Drug: Peficitinib | Astellas Pharma Inc | NULL | Recruiting | N/A | N/A | All | 3000 | Japan | |
| 3 | NCT03660059 (ClinicalTrials.gov) | September 27, 2018 | 26/8/2018 | A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX) A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who ... | A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to MTX A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of the Safety and Efficacy of ASP0 ... | Rheumatoid Arthritis (RA) | Drug: Peficitinib;Drug: Plaebo;Drug: Disease-modifying antirheumatic drugs (DMARDs) | Astellas Pharma China, Inc. | NULL | Completed | 18 Years | N/A | All | 385 | Phase 3 | China;Korea, Republic of;Taiwan |
| 4 | NCT02308163 (ClinicalTrials.gov) | August 8, 2014 | 2/12/2014 | A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Ha ... | Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the ... | Rheumatoid Arthritis | Drug: Peficitinib;Drug: Placebo;Biological: Etanercept | Astellas Pharma Inc | NULL | Completed | 20 Years | N/A | All | 509 | Phase 3 | Japan;Korea, Republic of;Taiwan |
| 5 | NCT02305849 (ClinicalTrials.gov) | July 25, 2014 | 1/12/2014 | A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Ha ... | Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the ... | Rheumatoid Arthritis | Drug: Peficitinib;Drug: Placebo;Drug: Methotrexate | Astellas Pharma Inc | NULL | Completed | 20 Years | N/A | All | 519 | Phase 3 | Japan |
| 6 | NCT01711814 (ClinicalTrials.gov) | September 26, 2012 | 19/10/2012 | A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in ... | A Phase 2 Open-Label, Noncomparative, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study A Phase 2 Open-Label, Noncomparative, Multicenter Extension Study to Evaluate the Long-term Safety a ... | Arthritis, Rheumatoid | Drug: peficitinib | Astellas Pharma Global Development, Inc. | Janssen Biotech, Inc. | Completed | 18 Years | N/A | All | 611 | Phase 2 | United States;Belgium;Bulgaria;Colombia;Czechia;Hungary;Mexico;Poland;Czech Republic |
| 7 | NCT01554696 (ClinicalTrials.gov) | July 6, 2012 | 13/3/2012 | A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Su ... | A Phase 2b, Randomized, Double-blind, Parallel-group, Placebo Controlled, Dose-finding, Multi-center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis in Patients Who Have Had an Inadequate Response to Methotrexate A Phase 2b, Randomized, Double-blind, Parallel-group, Placebo Controlled, Dose-finding, Multi-center ... | Arthritis, Rheumatoid | Drug: peficitinib;Drug: Placebo;Drug: methotrexate | Astellas Pharma Inc | NULL | Completed | 18 Years | N/A | All | 379 | Phase 2 | United States;Belgium;Bulgaria;Colombia;Czechia;Hungary;Mexico;Poland;Czech Republic |
| 8 | NCT01565655 (ClinicalTrials.gov) | June 19, 2012 | 27/3/2012 | A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis | A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Patients A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center ... | Arthritis, Rheumatoid | Drug: peficitinib;Drug: Placebo | Astellas Pharma Global Development, Inc. | NULL | Completed | 18 Years | N/A | All | 289 | Phase 2 | United States;Bulgaria;Czechia;Hungary;Mexico;Poland;Czech Republic |
| 9 | NCT01638013 (ClinicalTrials.gov) | June 13, 2012 | 9/7/2012 | A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study ... | Open-label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase 2b Study or Phase 3 Study of ASP015K Open-label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase 2b Study or Pha ... | Arthritis, Rheumatoid | Drug: Peficitinib | Astellas Pharma Inc | NULL | Completed | 20 Years | N/A | All | 843 | Phase 3 | Japan;Korea, Republic of;Taiwan |
| 10 | NCT01649999 (ClinicalTrials.gov) | March 1, 2012 | 23/7/2012 | A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Su ... | Phase 2b Study of ASP015K - A Double-Blind, Placebo-Controlled, Dose-Finding Study in Moderate to Severe Rheumatoid Arthritis Patients Phase 2b Study of ASP015K - A Double-Blind, Placebo-Controlled, Dose-Finding Study in Moderate to Se ... | Arthritis, Rheumatoid | Drug: peficitinib;Drug: Placebo | Astellas Pharma Inc | NULL | Completed | 20 Years | 75 Years | All | 281 | Phase 2 | Japan |